CRANBURY, N.J., Sept. 17,
2024 /PRNewswire/ -- IVIEW Therapeutics Inc., a
clinical-stage biotechnology company dedicated to advancing
innovative treatments for ocular diseases, today announced the
completion of patient recruitment for its Phase 1/2 clinical trial
evaluating IVW-1001, a novel TRPM8 agonist delivered via ophthalmic
eyelid wipe, for the treatment of signs and symptoms of dry eye
disease. The company anticipates reporting topline data in
the first quarter of 2025.
Advancing Toward Promising Results
"We are thrilled to have reached this significant milestone in
our clinical development program for IVW-1001," said Houman Hemmati, MD, PhD, Chief Medical Advisor
at IVIEW Therapeutics Inc. "Completing patient enrollment brings us
one step closer to potentially offering a new therapeutic option
for individuals suffering from dry eye disease. We are eagerly
awaiting the trial results and remain optimistic about the
potential impact on patient care."
A Step Forward in Innovative Ophthalmic Treatments
Bo Liang, PhD, MBA, Co-founder,
Chairman, and CEO of IVIEW Therapeutics Inc., commented, "The
completion of patient recruitment ahead of schedule is a testament
to the dedication of our clinical team and the interest from
the ophthalmic community. IVW-1001's novel mechanism of
TRPM8 activation and its innovative delivery through an ophthalmic
eyelid wipe could offer a differentiated treatment for dry eye
disease worldwide. We look forward to sharing our findings as
soon as they are available."
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage biotechnology
company focusing on innovative ophthalmic therapeutics. Driven by
the pursuit of cutting-edge science, we aim to develop
differentiated products that fulfill unmet medical needs. We invest
in novel mechanisms of action and advanced drug delivery technology
platforms to bring forward assets with potentially superior target
product profiles. Our innovative portfolio of small molecules and
gene therapy assets covers dry eye, myopia, conjunctivitis,
glaucoma, and presbyopia.
Located in Cranbury, New
Jersey, IVIEW operates a state-of-the-art 11,045 sq. ft.
laboratory and office space in the Princeton area. For additional information,
please visit our website at www.iviewtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/iview-therapeutics-inc-completes-patient-recruitment-for-phase-12-trial-of-ivw-1001-ophthalmic-eyelid-wipe-in-dry-eye-disease-patients-302250696.html
SOURCE IVIEW Therapeutics Inc.